For GlobeImmune, Early HCV Vaccine Data May Spark Coveted Partnership
This article was originally published in Start Up
Executive Summary
The first big reveal has arrived for GlobeImmune. On November 1, the company presented positive interim Phase II clinical trials data at the 2008 American Association for the Study of Liver Diseases meeting showing that its GI-5005 hepatitis C vaccine doubled viral clearance in all major patient populations tested in its randomized, multi-center trial. These data represent early but important evidence that a patient's natural immune response can be harnessed to positively influence important virologic endpoints with the potential to impact the course of chronic HCV infection.
You may also be interested in...
New Biomarker Impact on HCV Therapy and Clinical Trials
It's extraordinarily rare for a biomarker discovery to have a fast, clear-cut, and significant impact on a therapeutic area. But recent findings from a hepatitis C study--that a specific genetic variation strongly correlates with response to standard interferon-based therapy--could influence decision-making on when and how to treat certain HCV patients. What's more, the research may influence the design of clinical trials of new HCV agents and even trials in other diseases treated with interferon.
Newly Discovered Polymorphism May Have Immediate Impact in HCV
It's extraordinarily rare for a biomarker discovery to have a fast, clear-cut, and significant impact on a therapeutic area. But recent findings from a hepatitis C study--that a specific genetic variation strongly correlates with response to standard interferon-based therapy--could influence decision-making on when and how to treat certain HCV patients. What's more, the research may influence the design of clinical trials of new HCV agents and even trials in other diseases treated with interferon.
In Immunotherapy, Finally time for T Cells?
Immunotherapy has seen its share of failures in recent months, but T-cell oriented therapies are by no means dead in the water and therapeutic cancer vaccines continue to attract funding. This month START-UP profiles three companies that nevertheless have been able to attract funding . They aim to avoid the difficulties that have sunk other efforts to commercialize immunotherapies. The firms are transplanting T cells along with same-donor bone marrow to fight infection, delivering powerful cytokines and other therapeutic payloads via T-cell receptor targeting, and genetically enhancing the ability of T-cell receptors to recognize antigens before growing those T cells in culture and re-infusing them into a patient's body.